From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Epcoritamab has demonstrated a median overall survival of 21.6 months in patients with relapsed or refractory large B-cell lymphoma, as shown in the EPCORE NHL-2 trial 1.
Key Findings
- The EPCORE NHL-2 trial evaluated epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL, resulting in an overall response rate of 85% and a complete response rate of 61% 1.
- The median duration of complete response was 23.6 months, and the median overall survival was 21.6 months 1.
- Common treatment-emergent adverse events included cytopenias and cytokine release syndrome, with predictable timing and primarily low-grade events 1.
Mechanism of Action
- Epcoritamab works as a bispecific antibody that binds to CD3 on T cells and CD20 on B cells, redirecting T cells to eliminate malignant B cells 2, 3.
Administration and Monitoring
- The medication is administered as a subcutaneous injection with step-up dosing to minimize cytokine release syndrome, typically starting at 0.16 mg on day 1,0.8 mg on day 8,48 mg on day 15, and then 48 mg weekly for 12 weeks, followed by 48 mg every 4 weeks until disease progression or unacceptable toxicity 2, 3.
- Patients receiving epcoritamab should be monitored for cytokine release syndrome, neurologic toxicity, and infections, which are common adverse events 2, 3.
Comparison to Other Therapies
- Epcoritamab has demonstrated significantly better response rates and overall survival rates than chemoimmunotherapy, polatuzumab-based regimens, and tafasitamab-based regimens in third-line or later relapsed/refractory large B-cell lymphoma 4.
- No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL 4.